REVIEW ON AN ARB HAVING HIGHER ASSOCIATION LOWER DISSOCIATION INDEX FOR A RECEPTOR: A NEW TREND IN ACHIEVEMENT OF HYPERTENSION GOAL
Journal Title: Journal of Drug Discovery and Therapeutics - Year 2013, Vol 1, Issue 8
Abstract
OLMESARTAN medoxomil (angiotensin II receptor blockers (ARBs) having blood pressure lowering efficacy similar to other antihypertensive agents. Recent large-scale, randomized, controlled clinical trials have demonstrated that ARBs offer cardiovascular and renal protective benefits independent of their effects on systemic blood pressure (BP), which make them valuable as first-line antihypertensive agents, especially in high-risk patients. However, as is the case with other antihypertensive classes, monotherapy with the first-available ARBs may not provide sufficient BP reduction to achieve currently recommended BP goals in many patients. The angiotensin II receptor blockers (ARBs) are well tolerated and demonstrate significant BP reduction. Olmesartan medoxomil, an ARB, has been well studied and achieves significant BP lowering and goal achievement with good tolerability. Olmesartan medoxomil is the latest angiotensin II receptor include once-daily dosing, an absence of significant adverse reactions, a well-tolerated side-effect profile, and a cost-effective average wholesale price. Olmesartan medoxomil is currently being used as an alternative therapeutic antihypertensive agent for patients intolerant of angiotensin-converting enzyme inhibitors(ACEIs).
Authors and Affiliations
Bharat Bhushan*| Sunder Deep Pharmacy College, Ghaziabad, UP, India, Satish Kumar Sharma| Sunder Deep Pharmacy College, Ghaziabad, UP, India, Lalit Singh| Sunder Deep Pharmacy College, Ghaziabad, UP, India, Komal Gupta| Indira College of Pharmacy, Pune, Maharashtra, India
Keywords
Related Articles
- EP ID EP1443
- DOI -
- Views 465
- Downloads 48
Effect of 50% ethanolic extract of roots of Cissampelos pareira on some bio-chemical parameters to investigate the hepato-protective study in animal model (Rats)
In phytotherapeutic approach, the emphasis is on the development of a new drug whose extraction and fractionation have emanated on the basis of therapeutic activity. Cissampelos pareira Linn. (C. microcarpa, De Candolle)...
EVALUATION OF PKD2 GENE (G/C) POLYMORPHISM IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AMONG SOUTH INDIANS (MADURAI).
Polycystic kidney disease (PKD) is the leading causes of end-stage renal failure (ESRD) and a common indication of dialysis / renal transplantation. Autosomal dominant polycystic kidney disease (ADPKD) and autosomal rece...
“A CLINICAL STUDY TO EVALUATE THE EFFECTIVENESS OF AN AYURVEDIC INDIGINOUS COMPOUND IN CASES OF URDHWAGA AMLAPITTA w.s.r GERD”
Aim: To evaluate the efficacy of an ayurvedic indigenous compound in cases of urdhwaga amla-pitta. Introduction: Amla-pitta is one of the common clinical problems of our day to practice and it is increasing rapidly due t...
FDA'S NEW DRUG REVIEW PROCESS: AN OVERVIEW FROM OFFICIAL WEBSITE
Drugs are the vital and inevitable part of modern day treatment strategies. Drugs are always directly related with lives of human beings. There should be very strict approval process before getting permission for their m...
CURRENT SCENARIO OF PHARMACOVIGILANCE IN INDIA
Even though Pharmacovigilance is still in its infancy in India, it is not new to India and still there exists very limited knowledge about the discipline. While major advancements of the discipline of pharmacovigilance h...